InsiderDB
Sign inStart free trial
Got $3K from the company’s PAC

Rep. Lisa C. McClain sold Pfizer (PFE)

Rep. Lisa C. McClain (R-MI-9) · $1K–$15K · traded Aug 4, 2025

Got money from this company’s PAC

Pfizer’s PAC gave $3K to McClain’s campaign in the 2023–24 election cycle. See it on FEC.gov ↗

Company PACs are funded by employees, not the company itself, and give to many members of both parties. A donation doesn’t mean the trade was connected.

Transaction
Sold
Amount
$1K–$15K
Owner
Spouse
Traded
Aug 4, 2025
Disclosed
Sep 12, 2025
Days to disclose
39
Asset type
Stock
As filed
Pfizer, Inc. Common Stock
Industry
Drug Manufacturers - General · Healthcare
Official filing ↗All of McClain's tradesAll Congress trades in PFE

Other trades in this filing

All of McClain's trades →

Recent Congress trades in PFE

Company context for PFE

Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.

  1. PFEContract award·USAspending

    PFE: Department of Defense contract award

    4571868312!FENTANYL 100 MCG/2 ML VIAL 2ML

    First observed: Nov 8, 2026, 7:14 PM ESTEvent / period: May 18, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  2. PFEContract award·USAspending

    PFE: Department of Defense contract award

    4571877159!CYKLOKAPRON 1,000 MG/10 ML VL 10ML

    First observed: Nov 8, 2026, 7:14 PM ESTEvent / period: May 19, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  3. PFEContract award·USAspending

    PFE: Department of Defense contract award

    4571877630!CYKLOKAPRON 1,000 MG/10 ML VL 10ML

    First observed: Nov 8, 2026, 7:14 PM ESTEvent / period: May 19, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.